License and supply agreement with Genuine Health
RNS & Investor News
Appointment of Advanced NutriSolutions Inc./Select Ingredient as exclusive distributor for LPLDL® in the United States and Canada
17 February 2020
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its wholly-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed a distributor agreement with Advanced NutriSolutions Inc./Select Ingredient for the exclusive sales of ProBiotix's patented probiotic strain LPLDL® into the United States and Canada. Market exclusivity is linked to a six month time to first order and sales volumes
Under the terms of the agreement, Advanced NutriSolutions Inc./Select Ingredient will supply ProBiotix's cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LPLDL®, under an exclusive licence, to customers in the United States and Canada for inclusion into dietary supplements formulation.
Advanced NutriSolutions Inc./Select Ingredient was founded in 1994 by Dr. Bruce Howe. It supplies nutritional ingredients, contract manufacturing services, and finished products to the nutritional supplement industry. Advanced NutriSolutions Inc./Select Ingredient serves the United States and Canada from its facilities located in San Diego, California.
Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this distributor agreement with Advanced NutriSolutions Inc./Select Ingredient, which will expand LPLDL®'s reach and service level in the United States and Canada. Advanced NutriSolutions Inc./Select Ingredient was chosen as our partner in this important region because of their technical expertise in functional ingredients including probiotics, their industry reputation, and their manufacturing capabilities which allows them not only to sell LPLDL® as an ingredient but to also create custom formulation and products for customers."
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.
For further information, please contact:
|OptiBiotix Health Plc
Stephen O’Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP NOMAD)|
|Liam Murray / Jo Turner / Ludovico Lazzaretti||Tel: 020 7213 0880|
|finnCap (Broker)||Tel: 020 7220 0500|
|Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
|goetzpartners securities Limited||Tel: 0203 859 7725|
|Walbrook PR Ltd
|Mob: 07876 741 001|
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identiﬁed by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward looking statements reﬂect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020